Pósters de Ocrelizumab presentados en el congreso MSMilan 2023
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Progressive Multiple Sclerosis
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis. Analysis of the Largest Available Outcomes Database
Composite Confirmed Disability Worsening is a Useful Clinical Trial Endpoint for Multiple Sclerosis Focusing on Disability Progression
Ocrelizumab Dose Selection for Treatment of Paediatric Relapsing-Remitting Multiple Sclerosis: Updated Preliminary Pharmacokinetic, Safety and Efficacy Results from the OPERETTA 1 Study
Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase III OCARINA II Study
Utility and Implementation of a Federated Research Infrastructure to Assess Lack of Disease Stability as a Real-World Surrogate of PIRA, by Combining MS Clinical Trial and Real-World Cohort Data (The INTONATE-MS Consortium)
Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase Ib Dose-Finding OCARINA I Study
Combining Measures from Clinical Assessments, Imaging and Fluid Biomarkers at 1 Year to Predict Multiple Sclerosis Progression at 2 Years
Reduction of Intrathecal Immunoglobulin Levels With Ocrelizumab Treatment in Relapsing and Primary Progressive Multiple Sclerosis
The Patient Impact of 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Data from the Phase III OPERA and ORATORIO Studies
